OBI Invited to Present ADC Technology Platform and Chaired Sessions at Biologics World Korea 2025

OBI Pharma and AP Biosciences Sign Technology Collaboration Agreement to Develop Next-Generation ADC

OBI Pharma, Inc. Announces Board Resolution for Capital Reduction to Offset Accumulated Losses and Holds Material Information Press Conference

Announcement on behalf of Obigen’s BOD to resolve the reference date for conversion of employee stock options to common shares

Press Conference on Material Information Regarding the Board Resolution for Capital Reduction to Offset Accumulated Losses

The Company’s Board of Directors resolved to conduct a capital reduction to offset accumulated losses.

2024 Annual Report

Learn how we created value in 2024 and worked to pursue our purpose of enabling a healthier world.

Governance

Corporate
Overview​

Board of
Directors​

Special ​
Committee​

Integrity​

Internal
Audit​

Governance
Document​

Investor Relations